3 May 2023
On April 30th, 2023, Astellas Pharma Inc announced that it will acquire Iveric bio Inc for US$40.00 per share in cash for a total equity value of approximately US$5.9 billion.
Iveric Bio focuses on the discovery and development of novel treatments in the field of ophthalmology.
More, Source: Company’s Press Release